The Texas Department of State Health Services announced on March 25 that the infected dairy farm worker had direct contact with cattle presumed to be infected with avian influenza A(H5N1) prior to the onset of symptoms.

The Centers for Disease Control and Prevention confirmed the diagnosis through laboratory testing, marking the second human case of H5N1 ever identified in the United States and the first linked to exposure to dairy cattle rather than poultry or wild birds, according to CDC officials.

The patient’s primary symptom was eye inflammation, or conjunctivitis, with no severe respiratory illness reported at the time of the announcement, Texas DSHS said. The individual was described as “doing well” and receiving antiviral treatment consistent with standard influenza therapy. Health authorities reported the patient had been instructed to isolate to prevent potential onward transmission, although there was no evidence of efficient human-to-human spread of the virus, CDC spokespersons confirmed.

The infected worker was employed on a Texas dairy farm and had close, direct contact with sick dairy cows, which were later confirmed or presumed to be infected with H5N1, officials said. Prior to the human case, H5N1 had been detected in multiple dairy herds across several states, including Texas, Kansas, Michigan, and New Mexico, indicating a multistate outbreak in dairy cattle, according to CDC and state agriculture departments. CDC and Texas DSHS noted that the most plausible route of infection was exposure to secretions or excretions from infected cattle, particularly around the udder and milk, consistent with findings that H5N1 in cows was strongly associated with udder infection and milk contamination.

CDC classified the overall public health risk from H5N1 bird flu in the United States as “low” but emphasized that the risk was elevated for individuals with close, unprotected contact with infected animals, such as farm workers and veterinarians. There was no known person-to-person transmission of H5N1 in the U.S., including in connection with this Texas case, CDC officials said. Following the case, CDC continued active monitoring and testing of people with relevant animal exposures through national influenza surveillance systems to detect any unusual human flu activity.

The Texas case occurred amid a broader outbreak of H5N1 in U.S. dairy cattle, with confirmed affected herds in Texas, Kansas, Michigan, Idaho, South Dakota, New Mexico, Ohio, and North Carolina, according to CDC data. National records show that since early 2024, 71 human A(H5) infections have been reported in the United States, with 41 cases linked to exposure to dairy cattle. The total included two deaths. Experimental and epidemiological studies cited by CDC and academic sources found that H5N1 viruses in dairy cattle retained a strong preference for infecting birds and did not efficiently transmit via airborne routes between mammals, suggesting low pandemic potential in their current form.

Federal and state agencies, including CDC, the Food and Drug Administration, and Texas DSHS, have consistently stated that commercial milk remains safe for consumption. Pasteurization inactivates H5N1 virus, and milk from sick cows is required to be discarded or diverted, FDA officials said. Although viral fragments were detected in some commercial milk samples, FDA investigations confirmed these were non-infectious remnants and did not pose a direct consumer health risk. Public health guidance advises against consuming raw or unpasteurized milk and dairy products from infected or unknown-status herds due to theoretical exposure risks prior to pasteurization.

CDC recommends that workers on affected farms use appropriate personal protective equipment, including eye protection, masks or respirators, gloves, and protective clothing, and adhere to hygiene and biosecurity protocols when handling sick animals or contaminated materials. Authorities stress the importance of rapid reporting of illness in farm workers, prompt testing for influenza in symptomatic exposed individuals, and early antiviral treatment when H5N1 infection is suspected, as demonstrated in the management of the Texas dairy worker case.

The Texas DSHS alert and CDC confirmation have been incorporated into national situation summaries, distinguishing this case as the index human H5N1 infection linked to dairy cattle. Ongoing surveillance and research by CDC and academic partners continue to monitor the evolving outbreak and assess zoonotic transmission risks, with an emphasis on protecting agricultural workers and preventing further spillover events.

The proposed 3.1% overall payment increase for hospitals in fiscal year 2027 includes a 2.4% update to operating payment rates for general acute-care hospitals paid under the Inpatient Prospective Payment System, officials said. This net update is based on a projected 3.2% hospital market basket increase, reduced by a 0.8 percentage point productivity adjustment, according to the Centers for Medicare & Medicaid Services.

CMS estimates the proposed changes would increase total IPPS payments by about $1.9 billion compared with fiscal year 2026.

Hospitals that meet quality reporting requirements under the Hospital Inpatient Quality Reporting Program and demonstrate meaningful use of electronic health records would be eligible for the full update, CMS officials said. Those that do not successfully report quality data or fail to meet meaningful EHR use criteria would receive a reduced update consistent with existing IPPS policy, although the penalty structure follows prior rules rather than a new methodology specific to FY 2027.

However, the effective increase for some hospitals could be lower than the 2.4% headline rate after CMS factors in reductions in uncompensated care and outlier payments. The agency projects that Medicare Disproportionate Share Hospital and uncompensated care payments will decrease by approximately $564 million in FY 2027 compared with FY 2026, totaling $7.563 billion—a 3.3% decline from the previous year. This decrease is projected despite an expected rise in the national uninsured rate from 8.7% in FY 2026 to 9.1% in FY 2027, according to CMS estimates.

For hospitals meeting quality and EHR reporting requirements, CMS proposes a standardized amount of $6,967.87 for FY 2027, reflecting a 3.19% increase over FY 2026. The payment updates apply to general acute-care hospitals under IPPS that satisfy the Inpatient Quality Reporting and Promoting Interoperability program requirements, officials said.

The proposed rule, published in the Federal Register under docket number 2026-07203, also includes updates for long-term care hospitals, but the central acute-care payment increase remains the 2.4% operating rate update. CMS will accept public comments on the proposed rule and associated quality reporting policies through June 9, 2026, at 5 p.m. Eastern time. After reviewing comments, CMS plans to issue a final FY 2027 IPPS rule later in the year, with policies effective for discharges occurring between Oct. 1, 2026, and Sept. 30, 2027.

CMS is also proposing expansions to the Hospital Inpatient Quality Reporting Program, including the addition of three new measures. The agency plans to adopt the Excess Days in Acute Care After Hospitalization for Diabetes measure, which is claims-based, beginning with the FY 2029 IQR program year. Two new electronic clinical quality measures—the Hospital Harm Postoperative Venous Thromboembolism eCQM and the Advance Care Planning eCQM—would begin reporting for FY 2030. Additionally, CMS proposes to adopt five modified mortality measures incorporating both fee-for-service and Medicare Advantage patients into IQR starting in FY 2028, with plans to add these measures to the Hospital Value-Based Purchasing Program in FY 2032.

In the Hospital Readmissions Reduction Program, CMS proposes adding a new measure for the 30-day all-cause risk-standardized readmission rate following sepsis hospitalization, effective FY 2029. There are no proposed changes to the Hospital-Acquired Condition Reduction Program for FY 2027 beyond previously adopted policies. CMS also plans to update the definition of certified electronic health record technology for the Promoting Interoperability Program, aligning it with updates from the Office of the National Coordinator for Health Information Technology. Several updates to electronic clinical quality measures used in the Promoting Interoperability Program are proposed, including modifications to measure specifications and reporting requirements.

CMS is moving toward broader value-based accountability by proposing the establishment of CJR-X, a new mandatory nationwide episode-based payment model for lower extremity joint replacement beginning Oct. 1, 2027. Under CJR-X, acute-care hospitals would be financially accountable for spending and quality for hip, knee, and ankle joint replacement procedures during the inpatient stay and for 90 days post-discharge. Participation would be mandatory for all acute-care hospitals nationwide, except those in Maryland and those participating in the Transforming Episode Accountability Model, according to CMS. The agency also proposes updates to the TEAM model, including expanding eligible spinal fusion episodes, aligning attribution and quality measures with other CMS programs, and refining pricing methodologies.

Additional proposals include eliminating the alternate pathway for new technology add-on payments under IPPS and the transitional pass-through under the Outpatient Prospective Payment System, requiring breakthrough device designation technologies to meet the same criteria as non-breakthrough devices. For FY 2027, CMS proposes a maximum new technology add-on payment of $10,205 per case for the CARA System. The agency is also introducing new anti-discrimination requirements for graduate medical education payments, conditioning funding on residency and training programs not discriminating based on race, color, national origin, sex, age, disability, or religion. Similar standards would apply to nursing and allied health education programs and their accreditors.

CMS continues to develop the Birthing-Friendly Hospital designation introduced in the 2023 IPPS final rule and seeks public comment on expanding the designation using a more robust set of maternal quality care measures from the IQR program, including specific electronic clinical quality measures. The agency also proposes revisions to requirements for off-campus provider-based departments, clarifying criteria for demonstrating that such facilities serve the same patient population as the main provider and modifying rules for off-campus inpatient hospital services that do not serve patients in the same ZIP code as the main provider.

The FY 2027 IPPS proposed rule and supporting materials are available on the CMS website, and public comments are being accepted through June 9, 2026. CMS will finalize the rule later this year, with payment and quality reporting policies effective for discharges during the 2027 federal fiscal year.

The FDA said it recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg that had been distributed illegally outside Novo Nordisk’s authorized supply chain in the United States. The agency emphasized that it cannot verify the identity, quality, safety, or effectiveness of the seized counterfeit products, which may pose serious health risks to patients. Officials urged patients, wholesalers, retail pharmacies, and health care professionals not to use, distribute, or sell Ozempic products matching the identified counterfeit lot and serial numbers.

The counterfeit vials reportedly bear real lot numbers combined with illegitimate serial numbers, a key indicator of falsification, according to FDA and Novo Nordisk.

One cluster of counterfeit products carried the authentic lot number PAR0362 paired with serial numbers beginning with “51746517,” which the companies identified as illegitimate. Authorities clarified that the lot number PAR0362 alone is genuine, but any product with this lot number and serial numbers starting with “51746517” is counterfeit and unsafe. In a separate enforcement action, the FDA reported counterfeit Ozempic labeled with lot number NAR0074 and serial number 430834149057, and instructed stakeholders not to distribute, use, or sell products bearing this exact combination.

FDA and Novo Nordisk advised pharmacies and patients to carefully inspect labels, packaging, and device components, including verifying lot and serial numbers against FDA notices, as a primary method to detect suspect counterfeit semaglutide products. The agency also recommended obtaining semaglutide injections only through state-licensed pharmacies with valid prescriptions and warned against purchasing from unverified online sources.

While the FDA acknowledged receiving adverse event reports associated with the authentic lot through Novo Nordisk, officials said none of the reported events appeared directly linked to the identified counterfeit units as of the agency’s notice. However, because the contents and concentration of the counterfeit semaglutide are unknown, the FDA and Novo Nordisk warned that these products could result in ineffective treatment, under-dosing, or overdosing, all of which carry health risks, especially for patients with diabetes or obesity. Some seized counterfeit products included counterfeit needles, raising concerns about sterility and the potential for infection or transmission of blood-borne pathogens. Both the FDA and Novo Nordisk emphasized that neither entity can confirm the ingredients, sterility, or manufacturing conditions of the counterfeit injections, making any use potentially dangerous.

The FDA specifically highlighted that the seized counterfeit Ozempic entered the U.S. market outside Novo Nordisk’s authorized distribution channels, with online sellers and other unauthorized outlets identified as key concerns for counterfeit distribution. Novo Nordisk warned retail pharmacies and individuals to purchase Ozempic and other semaglutide products only through authorized distributors and cautioned that purchases from unverified online pharmacies increase the risk of receiving counterfeit products. The FDA discouraged consumers from buying prescription semaglutide without a valid prescription or at unusually low prices online, describing such offers as potential indicators of counterfeit medicines. The agency also urged reporting of suspected counterfeit or tampered medicines sold online through its criminal activity reporting channels.

The FDA is continuing its investigation into counterfeit Ozempic in the legitimate U.S. drug supply chain and has seized thousands of units as part of a broader enforcement effort. The agency is working closely with Novo Nordisk and federal partners to identify, investigate, and remove suspected counterfeit semaglutide products from the market. The investigation involves extensive visual examination and chemical testing to determine the composition, quality, and potential health risks of the seized products. The FDA said its investigation is ongoing and that it will update public safety communications as new counterfeit lots, serial numbers, or distribution channels are identified.

Novo Nordisk issued its own safety communication on April 14, 2025, confirming the distribution of “several hundred units” of counterfeit Ozempic 1 mg outside its authorized supply chain in the U.S. The company reiterated that lot number PAR0362 is authentic but stressed that products combining this lot with serial numbers starting with “51746517” are counterfeit and must not be used. Novo Nordisk advised retail pharmacies to validate their shipments using lot and serial number details and other authentication tools, and urged patients to inspect their Ozempic boxes and pens and to contact the company’s customer care line at 1-800-727-6500 or the FDA if they suspect their product may be counterfeit. The manufacturer supported the FDA’s efforts to remove counterfeit products from the supply chain due to the significant safety risks posed by unverified injections.

The FDA instructed patients, pharmacists, and clinicians to check all Ozempic 1 mg inventory for the specified counterfeit lot and serial number combinations and to quarantine any suspect products. Suspected counterfeit Novo Nordisk products can be reported directly to the FDA as suspected criminal activity through the agency’s reporting portal or local consumer complaint coordinators. Health care professionals and consumers are encouraged to report adverse events or product quality problems related to both suspected counterfeit and legitimate Ozempic products to the FDA’s MedWatch program. The FDA and Novo Nordisk also advised reporting websites selling counterfeit or tampered medicines to help enforcement efforts target illicit online operations. Patients concerned about the authenticity of their semaglutide products were directed to contact their pharmacist, prescriber, Novo Nordisk customer care, and the FDA and to stop using any product suspected to be counterfeit until its authenticity is verified.

Industry data from Kaufman Hall indicates that 2024 has been characterized by a period of stabilization for hospitals and health systems in the United States. The consulting firm reported improved operating margins and stable or neutral rating-agency outlooks for not-for-profit hospitals, signaling a halt in the financial deterioration that had affected many providers in previous years. Kaufman Hall’s analysis also highlighted a significant shift in merger and acquisition activity, with divestitures accounting for 62.5% of announced hospital and health system transactions in 2024, up from 31.1% in 2023 and exceeding the prior recent high of 56.2% in 2020. This trend points to ongoing restructuring within the sector, although no single major merger or acquisition dominated headlines during the early months of the year.

Divestitures accounted for 62.5% of announced hospital and health system transactions in 2024, up from 31.1% in 2023 and exceeding the prior recent high of 56.2% in 2020.

While bankruptcy remains a notable factor in healthcare finance, recent studies and reports emphasize that most hospital-related bankruptcy filings involve smaller organizations rather than large health systems. According to a Journal of Healthcare Management article, over half of healthcare organizations filing for bankruptcy during the study period chose Chapter 11 reorganization rather than Chapter 7 liquidation. The article noted that more than half of hospitals and health systems seeking bankruptcy protection ultimately fail to reorganize successfully and cease operations. However, larger hospitals affiliated with systems tend to have a higher likelihood of successful reorganization, underscoring the variability in bankruptcy outcomes across the sector.

A peer-reviewed exploratory study available through PubMed Central examined financial indicators associated with hospital bankruptcy. The study found that hospitals that permanently closed following bankruptcy were more likely to be for-profit entities and had lower cash flow to total debt ratios. Additional financial metrics correlated with bankruptcy classification included net patient revenue, accounts receivable, current ratio, total assets, debt-to-equity ratio, net operating profit margin, and the proportion of uncompensated care relative to net patient revenue. These findings provide insight into risk factors for hospital financial distress but do not correspond to any newly reported bankruptcy events in early 2024.

Legal and policy analysis published in the Yale Journal on Regulation discussed bankruptcy as a potential mechanism for public hospitals to avoid closure. The article outlined three primary options for financially distressed public hospitals: closure, privatization, or filing for bankruptcy. It argued that bankruptcy can sometimes preserve hospital operations that would otherwise end, a consideration for policymakers addressing public hospital financial challenges. This perspective reflects ongoing debates about the role of bankruptcy in the public hospital sector rather than reporting on a specific case.

The U.S. Department of Health and Human Services (HHS) has highlighted recurring concerns related to private equity (PE) ownership and debt-financed hospital acquisitions. A recent HHS report criticized some PE firms for using borrowed funds to purchase hospitals and subsequently selling off assets to generate short-term profits, potentially undermining long-term financial sustainability. The report referenced a health system that filed for bankruptcy on May 6, 2024, which was mandated to sell all remaining hospitals. While this case illustrates financial distress within the industry, it has not been identified as a singular major closure headline.

Kaufman Hall’s 2024 data also showed a decline in the credit quality of smaller parties involved in hospital transactions. The share of deals where the smaller party had a credit rating of A- or above fell to 2.8% in 2024 from 12.3% in 2023. This decline suggests increasing financial strain among smaller hospitals and health systems, contributing to the rise in divestitures and restructuring activity. Despite these pressures, no confirmed major hospital merger, closure, or bankruptcy event emerged as a dominant news story in the early part of 2024.

Overall, the available data and analyses from Kaufman Hall, HHS, peer-reviewed research, and legal scholarship collectively portray an industry experiencing mixed signals: signs of financial stabilization among larger not-for-profit hospitals alongside persistent distress and restructuring among smaller providers and certain segments. The absence of a single major headline merger, closure, or bankruptcy in the early months of 2024 reflects this complex and evolving landscape.

This testing schedule typically occurs on days 1, 3, and 5, with the day of exposure designated as day 0, according to the agency’s “Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2.” The guidance defines higher-risk exposure as being within six feet of a confirmed infected person or having unprotected direct contact with infectious secretions or excretions.

The CDC’s interim guidance outlines a testing regimen for healthcare personnel exposed to SARS-CoV-2, recommending serial viral testing immediately after exposure, but not earlier than 24 hours, followed by subsequent tests 48 hours apart.

Work restrictions are generally not required for asymptomatic healthcare workers following such exposures, except in specific circumstances. The CDC advises considering work restrictions for personnel who cannot undergo testing or wear source control for 10 days, those who are moderately to severely immunocompromised, healthcare workers caring for highly immunocompromised patients, or those working in units experiencing uncontrolled SARS-CoV-2 transmission, according to CDC officials. The guidance also notes that vaccination status does not alter the recommendation against routine work restrictions for asymptomatic exposed personnel.

The CDC’s webpage states that the interim guidance is subject to revision and references forthcoming updates to the “Guideline for Infection Control in Healthcare Personnel, 1998.” A draft of these updated recommendations is expected to be published in the Federal Register in the coming months, agency officials said.

In related public health developments, a federal judge ordered the restoration of multiple federal health websites and datasets on February 11, 2025, following their abrupt removal in late January. The order covered materials from the Department of Health and Human Services, the Food and Drug Administration, and the CDC, including information on HIV testing and prevention, contraceptive guidance, and vulnerability data related to natural disasters and emergencies. The government was required to restore the cited webpages by midnight Tuesday and identify additional physician resources by the end of that week, according to NPR reporting.

Meanwhile, the Department of Health and Human Services announced a significant workforce restructuring on March 27, 2025, which will reduce its staff by approximately 20,000 positions. The plan involves consolidating 28 divisions into 15 and is expected to cut about 3,500 FDA employees, 2,400 CDC employees, 300 Centers for Medicare & Medicaid Services staff, and 1,200 National Institutes of Health workers, according to a summary by law firm Polsinelli. The reduction includes roughly 10,000 direct job cuts and an additional 10,000 through buyouts or voluntary resignations, aiming to return HHS staffing levels to those seen before 2002.

Layoff notices began arriving as early as 5 a.m. EDT on a Tuesday in 2025, with entire divisions eliminated across multiple agencies, including much of the FDA’s communications and media affairs staff, The Hill reported. The reduction in force was scheduled to take effect on June 30, according to internal notices cited by the publication. StatNews reported on April 1, 2025, that thousands of employees across HHS and its subsidiary agencies received layoff notices, potentially affecting up to 10,000 workers. The report noted that some senior health officials were among those impacted, with the cuts linked to changes under the Trump administration and HHS leadership transitions under Secretary Robert F. Kennedy Jr.

Regarding workforce policies, HHS Instruction 990-3 governs telework, stating that participation is voluntary and subject to management approval based on applicable laws, the nature of the work, and work portability. The instruction references Office of Personnel Management guidance issued on February 3, 2025, allowing HHS to set overall telework levels and exclude certain positions from eligibility. Federal News Network reported that the CDC temporarily paused further telework approvals while clarifying internal policy details, reflecting ongoing adjustments to workforce flexibility.

These developments occur amid evolving federal health policies and agency restructuring efforts, with the CDC’s interim guidance and HHS workforce changes marking significant operational shifts in the nation’s public health infrastructure.

This represents a significant increase from 23% in 2025. Cost concerns outpaced other issues such as access to health care, cited by 17%, and obesity, mentioned by 8%, according to Gallup.

The West Health–Gallup survey found that 29% of U.S. adults identified health care costs as the most urgent health problem facing the country, the highest level recorded in more than two decades.

Nearly half of Americans, 47%, reported worry about their ability to afford health care in 2026, NBC News reported based on the same survey. The report linked this anxiety to rising prescription drug prices and the anticipated expiration of Affordable Care Act (ACA) subsidies. Concern over prescription drug costs has risen from 30% in 2021 to 37% in 2026, according to NBC News.

Gallup’s findings also show that seven in 10 Americans believe the U.S. health care system has major problems or worse. Within this group, 23% described the system as being in a state of crisis, a record high. Gallup indicated that the widespread concern about affordability reflects a broader negative perception of the health care system’s financial structure.

Additional polling underscores the prominence of affordability as a national issue. A March 31, 2026, summary by U.S. News reported that 61% of U.S. adults expressed a “great deal” of concern about health care accessibility and cost. The survey ranked health care as the foremost domestic issue, ahead of the economy, which was cited by nearly half of respondents. U.S. News noted that health care had held the top spot among American concerns from 2015 to 2020 before surging ahead by 10 points in 2026.

Data from the Kaiser Family Foundation (KFF) further illustrate the widespread burden of health care costs. KFF found that 44% of U.S. adults have difficulty affording health care, and 28% reported problems paying for care in the past 12 months. The foundation also reported that about two-thirds of adults are at least somewhat worried about affording care for themselves and their families. The financial strain is particularly acute among Hispanic adults, young adults, and the uninsured, KFF said.

Affordability issues are affecting health care behaviors and outcomes, according to an April 2026 survey by Imagine360. The survey found that 44% of respondents had skipped or postponed necessary care or medications due to cost. Among those who delayed care, 45% said their medical condition worsened. Additionally, 36% reported losing sleep over health care affordability during the past year, and 49% said they had cut back on essentials such as food, housing, and utilities to afford medical expenses.

Premium increases are adding to financial pressures. Polling by the PAN Foundation showed that 59% of Americans experienced higher health insurance premiums in 2026, with 41% reporting increases of 10% or more compared to the previous year. Premium hikes were especially common among people with Medicare (66%) and commercial insurance (69%). More than half of Americans, 54%, expressed concern about affording monthly premiums in 2026. Axios/Ipsos polling found that 69% of Americans worry insurance costs could rise, and majorities across political affiliations favor increased federal spending to reduce health care costs.

The growing concern over affordability comes as ACA subsidies are set to expire, potentially increasing out-of-pocket costs for many Americans. Policymakers are facing calls to address rising premiums and drug prices amid broad public frustration. The West Health–Gallup survey and other national polls suggest that health care affordability will be a central issue in the 2026 policy debate.

The shift toward outpatient care is largely driven by value-based care reimbursement models that prioritize quality and outcomes over service volume, officials said. Oracle, a technology research firm, summarized the transition as reimbursement tied to quality metrics, with incentives for prevention, screenings, and reducing readmission rates.

The Centers for Medicare & Medicaid Services defines value-based care as an approach focused on provider performance, patient experience, and quality of care rather than fee-for-service payments.

Industry experts note that value-based contracts reward hospitals for reducing unnecessary utilization. The American College of Surgeons explained that these contracts move payments away from the quantity of services rendered and toward the value delivered to patient populations. Oracle stated that providers receive bonuses for high-quality, collaborative care measured by outcomes such as mortality, readmissions, and preventive care use. CMS emphasized that value-based care supports managing patients’ overall health and coordinating care across providers to keep patients out of the hospital when safe. The Commonwealth Fund highlighted that efficiency is a key goal, encouraging providers to avoid using unnecessary resources.

Formal payment programs from Medicare and other payers increasingly favor quality and outcomes, further encouraging outpatient migration. Oracle cited CMS’s Hospital Value-Based Purchasing Program, which rewards acute care hospitals that improve inpatient care across mortality, complications, safety, patient experience, and infection rates. The ESRD Quality Incentive Program links dialysis facility payments to quality-of-care measures, according to Pressbooks at the University of West Florida. The Physicians Advocacy Institute noted that value-based contracts often include predetermined quality, financial, and patient-experience targets. Examples include pay-for-performance, shared savings, bundled pricing, capitation, and global budget contracts, which incentivize health systems to redesign care delivery, often by shifting services to outpatient settings where total episode costs can be lower.

Specialists are increasingly integrated into outpatient episode-based models tied to value-based care contracts. The Health Care Transformation Task Force specialty integration report detailed how payers like Blue Cross Blue Shield of Michigan use episode-based payments for procedures such as hip and knee replacements through programs like Orthopedics Episodes. BCBSM’s Value-Based Reimbursement for Specialists program offers performance-based incentives across multiple quality metrics. The report described these efforts as aiming to improve quality and increase specialists’ accountability for the total cost of care. Outpatient migration aligns with orthopedic, procedural, and post-acute episodes that can be managed outside the hospital when clinically appropriate.

Contract designs are evolving to link payments directly to measurable outpatient performance. The Physicians Advocacy Institute said value-based contracts provide incentives based on provider performance relative to efficiency and quality measures and are moving toward full-risk revenue models, including two-sided risk, direct-to-employer contracts, capitated models, and bundled payments. Quality metrics often include medication adherence, chronic condition control, and patient experience scores. The USC Schaeffer Center for Health Policy & Economics argued that value-based contracts must incentivize clinical decision-makers, typically physicians, to allocate treatment based on price and value. This structure encourages health systems to invest in outpatient pathways that improve metrics while controlling costs.

The broader goals of value-based care align with outpatient migration, according to CMS, which said the model focuses on what individuals value most and supports care teams managing overall health collaboratively. The Commonwealth Fund described value-based care as emphasizing effectiveness, efficiency, equity, patient-centeredness, safety, and timeliness. Oracle highlighted the importance of unified patient data shared across care teams to support better outcomes and seamless coordination. A scoping review published in PubMed Central noted that value-based health care aims to maximize health outcomes relative to cost using digital tools, multidisciplinary collaboration, and leadership. Moving care to outpatient settings can improve timeliness and patient-centeredness by reducing hospital exposure, provided health systems maintain quality and coordination.

However, implementation challenges may limit the pace of outpatient migration. The PMC scoping review identified barriers such as insufficient funding, the persistence of fee-for-service models, and resistance from healthcare professionals. The review also noted variability in outcomes across value-based care studies and concerns about insufficient reimbursements for providers. Successful adoption requires government support, appropriate reimbursement models, and organizational restructuring. The Physicians Advocacy Institute warned that contract methodologies for measuring quality and efficiency vary significantly by health plan, employer group, and region. For hospital systems, the sustainability of outpatient migration under value-based contracts depends on whether payments, staffing, data systems, and referral patterns can support the shift effectively.

The Phase 3 OptiTROP-Lung05 trial, conducted in China and led by Kelun-Biotech, demonstrated a 65% reduction in the risk of tumor progression when sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) was combined with Merck’s KEYTRUDA (pembrolizumab), compared with KEYTRUDA alone in previously untreated patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC). Kelun-Biotech announced the top-line results on Nov. 24, 2025, stating that the study met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful benefit.

According to Kelun’s press release, the combination therapy showed a positive trend in overall survival (OS), although the data remain preliminary and require longer follow-up for confirmation.

Multiple reports, including those from STAT and BioPharma Dive, noted the early survival benefit favoring sac-TMT but emphasized that the OS data are not yet mature. The topline announcements did not include detailed OS hazard ratios or median survival figures.

The trial enrolled patients with PD-L1 expression of 1% or higher and compared the sac-TMT plus KEYTRUDA regimen to KEYTRUDA monotherapy. Kelun’s newsroom highlighted that in a separate sac-TMT lung cancer study involving chemotherapy, median PFS was 8.3 months versus 4.1 months, with a hazard ratio of 0.35, underscoring the drug’s broader efficacy in lung cancer. Subgroup analyses reported by Kelun showed hazard ratios of 0.39 for HER2-zero and 0.31 for HER2-low patients, although these findings were not specific to the OptiTROP-Lung05 trial. An objective response rate (ORR) of 41.5% versus 24.1% was also cited in a separate lung cancer dataset posted by Kelun.

The OptiTROP-Lung05 trial is the first Phase 3 study to demonstrate the successful combination of an antibody-drug conjugate (ADC) targeting TROP2 with a PD-1 immune checkpoint inhibitor in the first-line treatment of advanced NSCLC, according to Kelun. The company described sac-TMT as a TROP2-directed ADC and views the data as supporting a potential new first-line treatment option for a subset of NSCLC patients. Merck, which partnered with Kelun-Biotech on the drug’s development, reiterated these findings in its ASCO 2026 materials, where the study was presented in the metastatic lung cancer oral abstract session.

Safety data from the trial were consistent with prior testing of sac-TMT, though detailed adverse event information was not included in the publicly available reports. Merck’s ASCO 2026 release noted ongoing global Phase 3 studies evaluating sac-TMT both in combination with pembrolizumab and as monotherapy. Kelun confirmed plans to engage with Chinese regulatory authorities to discuss potential approval filings based on the OptiTROP-Lung05 results.

The development of sac-TMT remains in late-stage clinical testing, with the OptiTROP-Lung05 findings serving as an important proof of concept for the Merck-Kelun collaboration in advancing ADC and immune checkpoint inhibitor combinations earlier in lung cancer treatment. The companies continue to explore the drug’s potential across multiple studies worldwide.

The study, published this month in a peer-reviewed journal and summarized by the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP), reported an adjusted risk ratio (aRR) of 0.86 for post-COVID-19 condition (PCC) among outpatients treated early with oral antivirals, indicating a 14% relative reduction in long COVID risk compared to untreated patients. The 95% confidence interval ranged from 0.78 to 0.93, supporting the statistical significance of the finding, according to the PubMed record titled “Early-Phase Oral Antiviral Use and Post-COVID-19 Condition in Outpatients.”

The CIDRAP summary further detailed that the estimated absolute risk of long COVID was 21.5% among antiviral recipients versus 25.1% in those who did not receive antivirals, yielding an adjusted risk difference of minus 4.14 percentage points.

This translated to a number needed to treat (NNT) of approximately 24.2, meaning that roughly 24 patients would require early antiviral therapy to prevent one case of long COVID under the study’s assumptions. The research focused on mildly ill, nonhospitalized patients infected during the Omicron era, emphasizing the outpatient setting.

The cohort study examined two specific oral antivirals: ensitrelvir and molnupiravir. Ensitrelvir recipients showed an aRR of 0.86 for PCC, with a 95% confidence interval from 0.79 to 0.95, while molnupiravir recipients had an aRR of 0.81, with a 95% confidence interval of 0.67 to 0.98. CIDRAP reported that among 1,698 patients treated with ensitrelvir, the NNT to prevent one long COVID case was 26.0, and among 385 molnupiravir recipients, the NNT was 17.9.

Beyond the reduced incidence of long COVID, the study also found that patients receiving early oral antivirals were less likely to report failure to return to usual health by day 84 after infection. The rates were 9.9% in the antiviral group compared to 12.9% among those not treated, with an adjusted risk ratio of 0.77 and a 95% confidence interval of 0.67 to 0.89, according to the PubMed abstract. This secondary outcome suggests that early antiviral treatment may facilitate faster recovery from COVID-19 symptoms.

The research was conducted during the Omicron variant wave and involved community-managed, nonhospitalized patients, making the findings most applicable to outpatient treatment initiated soon after diagnosis. However, the studies were observational and did not involve randomized controlled trials, so while the associations are statistically significant, they do not establish causality. The authors and CIDRAP noted that confounding factors and selection bias could influence the results, though consistent findings across different antiviral agents strengthen the observed association.

The broader context for these findings includes existing evidence that oral antivirals reduce acute severe outcomes of COVID-19. The U.S. Food and Drug Administration (FDA) authorized Paxlovid for mild-to-moderate COVID-19 in patients at high risk for progression to severe disease, recommending initiation within five days of symptom onset. FDA data cited an 88% reduction in COVID-19-related hospitalization or death in treated high-risk patients compared to placebo. Pfizer’s EPIC-HR trial interim analysis reported an 89% reduction in hospitalization or death when Paxlovid was administered within three days of symptom onset. This acute-phase efficacy provides a rationale for investigating whether early antiviral treatment also mitigates longer-term complications such as long COVID.

While the new cohort study and CIDRAP summary provide evidence linking early oral antiviral use to both a modest reduction in long COVID risk and improved recovery speed, the observational nature of the data means that further research, including randomized trials, will be needed to confirm these associations and clarify mechanisms. The findings contribute to a growing body of literature examining the potential benefits of early antiviral therapy beyond preventing severe acute illness.

The outbreak, which had previously been reported at 91 deaths out of 350 suspected cases, is centered in eastern Democratic Republic of Congo, with confirmed transmission in Ituri province. According to the World Health Organization, 30 cases have been confirmed in Ituri, while the broader suspected caseload exceeds 500, with one official estimate at 513 suspected cases. Health authorities have expressed concern that the outbreak has spread beyond a single locality, raising the possibility of wider geographic transmission.

Health Minister Samuel Roger Kamba said the 131 deaths reported as of May 19, 2026, represent fatalities identified in the community and are not all necessarily confirmed Ebola deaths.

The World Health Organization declared the outbreak a public health emergency of international concern, citing the rapid pace and scale of transmission. This designation was supported by the Africa Centres for Disease Control and Prevention, which termed the situation a continental public health emergency. WHO officials clarified that the outbreak is not being treated as a pandemic but as a significant cross-border public health threat. An emergency meeting was convened by WHO to coordinate the international response.

The Ebola virus strain involved is identified as the Bundibugyo strain. Health reports indicate there is no approved vaccine or therapeutic treatment for this strain, a factor contributing to heightened concern among scientists and health agencies. WHO and the U.S. Centers for Disease Control and Prevention emphasized the need for rapid surveillance, noting that the outbreak may be expanding faster than case confirmation can keep pace. The strain is described as highly contagious and particularly dangerous in settings with weak containment measures.

Cross-border spread has been confirmed with two cases reported in Uganda, including one death. WHO stated that the Ugandan cases involved individuals who had traveled from DR Congo. In response, WHO has advised cross-border screenings between DR Congo and Uganda to help limit further spread. The movement of people across borders is central to the current response strategy.

A U.S. citizen and doctor working in DR Congo was confirmed to have contracted Ebola. The medical missionary organization Serge identified the patient as one of its doctors who had been exposed through work in the outbreak area. Germany announced readiness to receive and treat the American patient. Reports from CBS indicated that at least six Americans may have been exposed to the virus, though this figure has not been formally confirmed by WHO or CDC.

The CDC stated that the risk to the United States remains relatively low but that preventive measures are in place. U.S. authorities have begun monitoring travelers arriving from affected regions and have imposed entry restrictions on non-U.S. passport holders who have been in Uganda, DR Congo, or South Sudan within the past 21 days. The U.S. issued a Level 4 travel warning for DR Congo, its highest advisory level, discouraging travel to the area. Additionally, screening of air passengers from outbreak-hit areas has commenced, and visa services for some travelers from affected countries have been temporarily suspended.

The outbreak was first confirmed in late the previous week before the May 19 update. Health officials have indicated that the number of cases may continue to rise as investigations and surveillance efforts proceed. The lack of an approved vaccine and the rapid spread of the Bundibugyo strain remain key challenges for containment efforts. WHO and CDC continue to coordinate international response activities aimed at limiting the outbreak’s expansion.